Louise Barbier

Louise Barbier

Auto-generated profile, based on publicly available information

Louise Barbier

University of Auckland Auckland New Zealand

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in HPB
Verified
Journal Article
Open access
PDF file
LBLouise Barbier
Louise Barbier
WJWisam Jamal
Wisam Jamal
SDSafi Dokmak
Safi Dokmak
BABéatrice Aussilhou
Béatrice Aussilhou
OCOlivier Corcos
Olivier Corcos
SASauvanet Alain
Sauvanet Alain
Background The aim was to assess the outcome of a total pancreatectomy (TP). Methods From 1993 to 2010, 56 patients underwent an elective TP for intraductal papillary mucinous neoplasia (n = 42), endocrine tumours (n = 6), adenocarcinoma (n = 5), metastases (n = 2) and chronic pancreatitis (n = 1). Morbidity and survival were analysed. Long-term survivors were assessed prospectively using quality-of-life (QoL) questionnaires. Results Five patients developed gastric venous congestion intra-operatively. Post-operative morbidity and mortality rates were 45% and 3.6%, respectively. An anastomotic ulcer occurred in seven patients, but none after proton pump inhibitor therapy. There were five inappropriate TPs according to definitive pathological examination. Overall 3- and 5-year survival rates were 62% and 55% respectively; five deaths were related to TP (two postoperative deaths, one hypoglycaemia, one ketoacidosis and one anastomotic ulcer). Prospective evaluation of 25 patients found that 14 had been readmitted for diabetes and that all had hypoglycaemia within the past month. The glycated haemoglobin (HbA1c) was 7.8% (6.3–10.3). Fifteen patients experienced weight loss. The QLQ-C30 questionnaire showed a decrease in QoL predominantly because of fatigue and diarrhoea, and the QLQ-PAN26 showed an impact on bowel habit, flatulence and eating-related items. Discussion Morbidity and mortality rates of TP are acceptable, although diabetes- and TP-related mortality still occurs. Endocrine and exocrine insufficiency impacts on the long-term quality of life.

1 September 2014 in Journal of Visceral Surgery
Verified
Journal Article
Closed access
LBL. Barbier
L. Barbier
RSRegis Souche
Regis Souche
KSK. Slim
K. Slim
PAP. Ah-Soune
P. Ah-Soune

1 January 2011 in HPB
Verified
Journal Article
Closed access
PDF file
LBLouise Barbier
Louise Barbier
OTOlivier Turrini
Olivier Turrini
EGEmilie Grégoire
Emilie Grégoire
FVFrédéric Viret
Frédéric Viret
YTYves-Patrice Le Treut
Yves-Patrice Le Treut
JDJean Robert Delpero
Jean Robert Delpero

1 December 2019 in Journal of Hepatology
Verified
Journal Article
Closed access
LBLouise Barbier
Louise Barbier
JNJean-Charles Nault
Jean-Charles Nault
FDFanny Dujardin
Fanny Dujardin
BSBéatrice Scotto
Béatrice Scotto
MBMarie Besson
Marie Besson
YBYannick Bacq
Yannick Bacq

1 January 2011 in International Journal of Hepatology
Verified
Journal Article
Open access
PDF file
LBL. Barbier
L. Barbier
FMF. Muscari
F. Muscari
SGS. Le Guellec
S. Le Guellec
APA. Pariente
A. Pariente
POP. Otal
P. Otal
BSB. Suc
B. Suc
Background. Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma in Child A patients.Aims. To address the question of sorafenib as neoadjuvant treatment.Methods. We describe the cases of 2 patients who had surgery after sorafenib.Results. The patients had a large hepatocellular carcinoma in the right liver with venous neoplastic thrombi (1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had decreased in size with a necrotic component. A right hepatectomy with thrombectomy was performed, and histopathology showed 35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free since then.Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a curative intent.

10 October 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
LBLouise Barbier
Louise Barbier
MRMaxime Ronot
Maxime Ronot
BABéatrice Aussilhou
Béatrice Aussilhou
FCFrançois Cauchy
François Cauchy
CFClaire Francoz
Claire Francoz
JBJacques Belghiti
Jacques Belghiti